AP4S1 is a subunit of the Adaptor Protein 4 (AP-4) complex, a key player in intracellular protein trafficking. It helps transport proteins from the trans-Golgi network (TGN) to endosomes and lysosomes, essential for various cellular processes, including recycling and sorting proteins.
Disruption in this function leads to conditions like AP-4 deficiency, which manifests as severe developmental and neurological symptoms.
The AP4S1 gene provides instructions for making a protein called the sigma-1 subunit of the adaptor protein complex 4 (AP-4).
AP-4 helps transport important proteins inside cells, especially in nerve cells. It works in a part of the cell called the trans-Golgi network (TGN) to send proteins to the right places in the cell.
When AP4S1 doesn’t work correctly because of mutations, this system breaks down, leading to problems with protein movement and causing damage to nerve cells.
Mutations in the AP4S1 gene cause a condition called AP-4-associated hereditary spastic paraplegia (AP-4-HSP).
This is a rare, inherited disease that affects movement and development. It usually starts in early childhood with symptoms like weak muscles, delays in reaching motor milestones, seizures, and difficulty with learning.
As the condition worsens, children often develop stiffness in their legs, making walking difficult, and they may lose the ability to walk independently. Other issues may include problems with bladder control, deformities in the feet, and behavioral challenges like hyperactivity and impulsivity.
AP-4-HSP is diagnosed through genetic testing, which looks for harmful changes in the AP4S1 gene. There is no cure, so treatment focuses on helping affected individuals manage symptoms, such as physical therapy for muscle strength and medications for seizures.
Since AP-4-HSP is passed down from parents to children in an autosomal recessive way, genetic counseling is important for families to understand the risks and options for future pregnancies.
AP4S1 testing is particularly relevant for individuals exhibiting symptoms of AP-4 deficiency. These symptoms may include delayed development, intellectual disability, and motor impairments.
Testing is especially important for children or adults who show signs of progressive ataxia, which is common in this condition. Patients with a family history of developmental delays or known genetic disorders related to AP-4 should also be considered for testing.
Testing is also essential for families with a history of AP-4-related disorders, as genetic counseling can help guide family planning decisions and inform recurrence risks. Understanding whether an individual carries a pathogenic variant can provide valuable information for both the patient and their family members.
The following section briefly outlines testing and results interpretation:
AP4S1 is typically tested through genetic analysis, which requires a blood or saliva sample. There are no specific preparation requirements for the patient, although ensuring that the sample is properly collected and handled is important for accurate results.
Next-generation sequencing (NGS) is a common method for detecting AP4S1 mutations. This technique allows clinicians to scan the entire AP4S1 gene for variants, helping identify disease-causing mutations.
AP4S1 is not a biomarker with "high" or "low" levels in the traditional sense. Instead, it is evaluated based on the presence of pathogenic variants within the gene.
A healthy individual will not have mutations in the AP4S1 gene, while individuals with AP-4 deficiency will have specific disease-causing variants.
When pathogenic variants are identified in the AP4S1 gene, they interfere with the function of the AP-4 complex, leading to a disruption in cellular trafficking processes that ultimately manifests in the symptoms associated with AP-4-Associated Hereditary Spastic Paraplegia.
The prognosis for patients with AP-4-HSP involves progressive developmental delays, intellectual disabilities, and motor impairments like spastic diplegia, with symptoms worsening over time without proper management.
The condition is chronic, and there is no cure, but supportive care can help manage symptoms.
Multidisciplinary care is essential for individuals with AP-4 deficiency. This may include physical therapy, occupational therapy, speech therapy, and educational support to help manage developmental and motor impairments.
There is currently no specific treatment for AP4S1 mutations, but ongoing research is exploring potential therapies that may improve patient outcomes.
Alecu J, Schierbaum L, Ebrahimi-Fakhari D. AP-4-Associated Hereditary Spastic Paraplegia. 2018 Dec 13 [Updated 2025 Feb 6]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535153/
AP-4-Associated Hereditary Spastic Paraplegia (AP-4-HSP) - Symptoms, Causes, Treatment | NORD. (n.d.). Rarediseases.org. https://rarediseases.org/rare-diseases/ap-4-associated-hereditary-spastic-paraplegia/
Carmona, S., Marecos, C., Amorim, M., Ferreira, A. C., Conceição, C., José Brás, Duarte, S. T., & Guerreiro, R. (2018). AP4S1 splice-site mutation in a case of spastic paraplegia type 52 with polymicrogyria. Neurology Genetics, 4(5). https://doi.org/10.1212/nxg.0000000000000273
Gene Database. (2024). AP4S1 Gene - GeneCards | AP4S1 Protein | AP4S1 Antibody. Genecards.org. https://www.genecards.org/cgi-bin/carddisp.pl?gene=AP4S1
Hardies, K., May, P., Djémié, T., Tarta-Arsene, O., Deconinck, T., Craiu, D., AR working group of the EuroEPINOMICS RES Consortium, Helbig, I., Suls, A., Balling, R., Weckhuysen, S., De Jonghe, P., & Hirst, J. (2015). Recessive loss-of-function mutations in AP4S1 cause mild fever-sensitive seizures, developmental delay and spastic paraplegia through loss of AP-4 complex assembly. Human molecular genetics, 24(8), 2218–2227. https://doi.org/10.1093/hmg/ddu740
Jordan, C., Geisel, G., Alecu, J. E., Zhang, B., Sahin, M., & Ebrahimi-Fakhari, D. (2021). Disease Severity and Motor Impairment Correlate With Health-Related Quality of Life in AP-4-Associated Hereditary Spastic Paraplegia. Neurology. Genetics, 7(4), e605. https://doi.org/10.1212/NXG.0000000000000605
Tessa, A., Battini, R., Rubegni, A., Storti, E., Marini, C., Galatolo, D., Pasquariello, R., & Santorelli, F. M. (2016). Identification of mutations in AP4S1/SPG52 through next generation sequencing in three families. European journal of neurology, 23(10), 1580–1587. https://doi.org/10.1111/ene.13085